INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested
 NantKwest’s antibody-targeted NK cell line, haNK, which is engineered for increased antibody-dependent cell-mediated cytotoxicity and activation, showed increased resistance to hypoxic conditions as seen in suppressive tumor microenvironments NantKwest’s PD-L1 t-haNK cells, haNK cells engineered
View HTML
Toggle Summary NantKwest Announces Proposed Public Offering of Common Stock
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 24, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public
View HTML
Toggle Summary NantKwest Announces Pricing of Public Offering of Common Stock
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 25, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000 shares at a price
View HTML
Toggle Summary NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 29, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock
View HTML
Toggle Summary Engineered Killer Immune Cells Target Tumours and Their Immunosuppressive Allies View HTML
Toggle Summary ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins
Preclinical results show this next generation Adeno (hAd5) vaccine, which targets both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins, generates CD4+ and CD8+ T-cell responses, both of which can form long-term immune memory.  Inclusion of nucleocapsid in this vaccine construct potentially
View HTML